戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.
2 ecommend an intranasal corticosteroid over a leukotriene receptor antagonist.
3  leukotriene B4 receptor but not a cysteinyl-leukotriene receptor antagonist.
4 without a low-dose inhaled glucocorticoid or leukotriene-receptor antagonist.
5 mple, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.
6 successfully identified clinically effective leukotriene receptor antagonists.
7 ing long-acting muscarinic antagonist and 13 leukotriene receptor antagonists.
8 a, which was treated with antihistamines and leukotriene receptor antagonists.
9 ticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists.
10 roids (21.5%; 95% CI: 20.7%-22.3%; p<0.001), leukotriene receptor antagonists (13.4%; 95% CI: 12.9%-1
11 long-acting beta agonists, theophyllines, or leukotriene-receptor antagonists, adjusted stepwise acco
12  treatment with H1 and H2 receptor blockers, leukotriene receptor antagonist and consideration for pr
13 ge in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticostero
14                                              Leukotriene receptor antagonists and long-acting beta2-a
15 osteroids [topical (swallowed) or systemic], leukotriene receptor antagonists and, most recently, bio
16  mouse model, we administered montelukast, a leukotriene receptor antagonist, and diabetes-related re
17  daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS trea
18 include daily inhaled corticosteroids, daily leukotriene receptor antagonists, and combination therap
19 s, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently pro
20                                              Leukotriene-receptor antagonists are the first novel cla
21                                              Leukotriene-receptor antagonists as monotherapy improved
22               Controlled trials suggest that leukotriene receptor antagonists can improve lung functi
23    We aimed to assess whether montelukast, a leukotriene receptor antagonist, can improve symptoms or
24 fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up).
25                                              Leukotriene-receptor antagonists either as monotherapy o
26 ray of options, including H2 antihistamines, leukotriene receptor antagonists, glucocorticosteroids,
27                                         Oral leukotriene receptor antagonists have been shown to have
28 agents such as cromolyn and the new class of leukotriene receptor antagonists have demonstrated benef
29 ukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists have shown efficacy in
30 ay disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmac
31 ium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in
32 nical efficacy of inhaled glucocorticoids to leukotriene receptor antagonists in children with mild t
33 vide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose sympt
34 he effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatment of pos
35 s, long-acting inhaled beta2-stimulants, and leukotriene receptor antagonists, increased year after y
36                Another potential spin-off of leukotriene-receptor antagonists is that they also seem
37 emists in the design of potent and selective leukotriene receptor antagonists-leukotriene structural
38 to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting beta2-agoni
39 steroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) o
40        Long-acting beta2-agonists (LABA) and leukotriene receptor antagonists (LTRA) are two principa
41 = 973), ICS monotherapy (n = 2623), ICS plus leukotriene receptor antagonists (LTRA; n = 338), or ICS
42 edication (long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline, or
43 ment with ICSs alone (n = 1758) or ICSs plus leukotriene receptor antagonist (LTRAs; n = 354) or ICSs
44                         The use of cysteinyl leukotriene receptor antagonists (LTRAs) for asthma ther
45                                The growth of leukotriene receptor antagonists (LTRAs) has been extrao
46     Recent evidence suggests that the use of leukotriene receptor antagonists (LTRAs) in addition to
47  describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to
48 hieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection agai
49                                              Leukotriene-receptor antagonists (LTRAs) are recommended
50 yclo-oxygenase inhibitor indomethacin or the leukotriene receptor antagonist MK-571, indicating that
51 o examine a potential protective role of the leukotriene receptor antagonist montelukast on future ri
52               New dispensed prescription for leukotriene receptor antagonist montelukast or control m
53            Second line therapies include the leukotriene receptor antagonist montelukast, and other a
54 ceptor antagonist, cetirizine, and cysteinyl-leukotriene receptor antagonist, montelukast, as well as
55                                          The leukotriene receptor antagonists, montelukast, zafirluka
56 al need to use alternative therapies such as leukotriene receptor antagonists or DNase I that target
57  for a daily inhaled corticosteroid, a daily leukotriene receptor antagonist, or a mast cell stabiliz
58 the approved dose) plus H(2)-antihistamines, leukotriene receptor antagonists, or both.
59  the approved dose plus H(2)-antihistamines, leukotriene receptor antagonists, or both.
60             Montelukast, an oral, once-daily leukotriene receptor antagonist, provides protection aga
61 ected animals with MC-stabilizing drugs or a leukotriene receptor antagonist restores vascular integr
62  useful add-on therapies for AR include oral leukotriene receptor antagonists, short bursts of a nasa
63                                              Leukotriene receptor antagonists such as montelukast hav
64                      The published data with leukotriene-receptor antagonists such as montelukast or
65 ational method to titrate corticosteroid and leukotriene receptor antagonist therapy.
66   We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patient
67 nist, long-acting muscarinic antagonist, and leukotriene receptor antagonist was hospitalized with a
68 choconstriction by a single oral dose of the leukotriene receptor antagonist zafirlukast was assessed